FINAL PUBLIC MEETING
UNA Hotels Decò - Roma
November 23 - 24, 2026

Targeted T cell therapy to cure immune diseases- geneTIGA and beyond

Monday 23rd November 2026 - DAY I

AGENDA

geneTIGA achievements and the technology field

09:15 – 10:00 *Registration and welcome coffee*

10:00 – 10:10 **Opening and housekeeping**
10:10 – 10:40 **Welcome and Consortium overview**
Petra Reinke and Dimitrios Wagner
10:40 – 11:05 **IgA-TCRs moving to the clinic** (20 min + 5 min discussion)
Johanna Olweus
11:05 – 11:30 **Modernizing gene transfer – from random insertion to precise gene editing** (20 min + 5 min discussion)
Dimitrios Wagner or team

11:30 – 11:45 *Coffee break*

11:45 – 12:10 **Standards for genome editing assessment and safety** (20 min + 5 min discussion)
Toni Cathomen or Jacob Corn / team
12:10 – 12:35 **Identifying the patients in need: IgA pathophysiology** (20 min + 5 min discussion)
Katherine Bull
12:35 – 13:00 **Cell and Nano therapies in Organ Transplantation** (20 min + 5 min discussion)
Giuseppe Remuzzi - PHOENIX consortium

13:00 – 14:00 *Lunch*

14:00 – 14:25 **Patient perspective** (20 min + 5 min discussion)
Patient representative [TBD]
14:25 – 14:50 **Biomarkers for Cell Product ID Cards and Therapy Monitoring** (20 min + 5 min discussion)
Hans-Dieter Volk and Kerstin Jülke CheckImmune
14:50 – 15:15 **CD19-CAR T cells without lymphodepletion for autoimmune disease** (20 min + 5 min discussion)
Jonathan Hogan, Cabaletta Bio
15:15 – 15:40 **In vivo CAR/TCR gene therapies** (20 min + 5 min discussion)
Matthias Bozza, CPTx GmbH

15:40 – 16:10 *Coffee break*

16:10 – 16:40 **Panel: technologies for next waves of T cell immunotherapies**
Jacob Corn, Jonathan Hogan, Matthias Bozza, Luca Gattinoni, Peter Mouritzen
Moderator: Dimitrios Wagner
Evening **Poster session**, *rolling into dinner, followed by networking social*

Funded by the European Union

Funded by the European Union under Grant Agreement Nr. 101057438. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

Organization and Graphic project by: Innovation Acta

FINAL PUBLIC MEETING

UNA Hotels Decò - Roma

November 23 - 24, 2026

Tuesday 24th November 2026 - DAY II

AGENDA

Translation, patients and the EU funding landscape

09:30 – 09:40 **Welcome back**

09:40 – 10:05 **Personalised T-cell therapy for viral complications in immunosuppressed patients with and without transplantation** (20 min + 5 min discussion)
Britta Eiz-Vesper

10:05 – 10:30 **T-FITNESS: Building T Cells That Don't Burn Out** (20 min + 5 min discussion)
Luca Gattinoni

10:30 – 11:00 *Coffee break*

11:00 – 11:25 **EU funding for ATMP development** (20 min + 5 min discussion)
Mirko Lo-Cicero, HaDEA

11:25 – 12:10 **Panel: European innovation in the ATMP space**
Petra Reinke, Fadi Issa, Goran Josipović, Richard Day, Mirko Lo-Cicero; Moderator [organized via InnActa]

12:10 – 12:25 **Closing remarks and consortium next steps** (20 min + 5 min discussion)
Petra Reinke and Dimitrios Wagner

12:25 – 12:35 **EAB statement**

12:35 – 14:00 *Farewell lunch and networking, end of open event*

14:00 – 15:30 **geneTIGA restricted meeting**

All talks are 20 minutes plus 5 minutes discussion unless otherwise noted. Draft programme – subject to confirmation.

Funded by the European Union

Funded by the European Union under Grant Agreement Nr. 101057438. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

Organization and Graphic project by: InnovationActa

POSTER SESSION - all partners - DAY I Evening

The following list is a preliminary plan of posters of geneTIGA Consortium.

Guest posters are welcome; abstract submission encouraged.

TU-BS: IgA binders

OUS: IgA-TCR discovery

Charité: IgA-specific CAR engineering – Roberts Karklins

Charité: CRISPR-HDR guided serine recombinases enable precise integration of large transgenes for multifunctional T cell engineering – Jonas Kath

Charité: Base-editor mediate knock-ins for safer multiplex CAR T cells – Viktor Glaser

Charité: Modulating CAR-T homing via LNP-mRNA transfer of homing receptors – (TBD)

InnActa: Outreach and dissemination

UKLFR: Advancing methods for multi-platform off-target nomination in genome editing -Carla Fuster-Garcia;

UKLFR: Assay to predict the worst - clonal outgrowth

ETHZ: Off-target analysis for TCR-replacement and CAR integration (TRAC, TRBC1/2)

ETHZ: impact of DNA-PK inhibitors on gene editing outcomes

TissUse: Modeling Motility and Efficacy of T-cell Therapies against IgA-Nephropathy on Chip- Rosanna Stolberg

TissUse: A human kidney MPS to assess antigen specificity and inflammatory risk of IgA-targeting T cells- Eva-Maria Dehne

CheckImmune: Olink and scRNA-seq for patient monitoring – (TBD)

CheckImmune: Immune Biomarkers for Preclinical & Clinical Immune Monitoring - Kerstin Juelke

Potentially **AU + Charité**: Essential gene knock-in – maybe Christian

Charité: IgAN urine analysis for prediction of disease progression – Lennard Ostendorf

OUXF: Spatially resolved glomerular injury programmes define progression in IgA nephropathy- Jessica Kepple

OUXF: In Vivo Evaluation of an IgA targeting Engineered T Cell Therapy for the Treatment of IgA Nephropathy- Merve Bilici

GENOS: Large-Scale Profiling of IgA Glycosylation in Patients with IgA Nephropathy- Jasminka Krištić

GENOS: From Genes to Glycans: Mapping the Genetic Network Regulating IgA Glycosylation- Goran Josipović

EKPF: Outreach efforts (IgAN Friends)

Funded by the European Union

Funded by the European Union under Grant Agreement Nr. 101057438. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

Organization and Graphic project by: InnovationActa